Common Contracts
4 similar Purchase Agreement contracts by Alere Inc., Inverness Medical Innovations Inc
Alere Inc. $425,000,000 6.500% Senior Subordinated Notes due 2020 PURCHASE AGREEMENTPurchase Agreement • May 16th, 2013 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
Introductory. Alere Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers named in Schedule A (the “Initial Purchasers”) $425,000,000 aggregate principal amount of its 6.500% senior subordinated notes due 2020 (the “ Original Notes”). The Company’s obligations under the Original Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior subordinated basis, by each of the Subsidiaries (as defined below) listed on the signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Original Notes and the Guarantees are referred to herein as the “Securities.” The respective principal amounts of the Original Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Original Notes are to be issued under an indenture dated as of May 12, 2009 (the “Base Indenture”
Alere Inc. $450,000,000 7.250% Senior Notes due 2018 PURCHASE AGREEMENTPurchase Agreement • November 30th, 2012 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
Introductory. Alere Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers named in Schedule A (the “Initial Purchasers”) $450,000,000 aggregate principal amount of its 7.250% senior unsecured notes due 2018 (the “Original Notes”). The Company’s obligations under the Original Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior unsecured basis, by each of the Subsidiaries (as defined below) listed on the signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Original Notes and the Guarantees are referred to herein as the “Securities.” The respective principal amounts of the Original Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Original Notes are to be issued under an indenture dated as of August 11, 2009 (the “Base Indenture”) as
Alere Inc. $400,000,000 8.625% Senior Subordinated Notes due 2018 PURCHASE AGREEMENTPurchase Agreement • September 21st, 2010 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
Introductory. Alere Inc., a Delaware corporation (formerly, Inverness Medical Innovations, Inc., the “Company”), proposes to issue and sell to the several initial purchasers named in Schedule A (the “Initial Purchasers”) $400,000,000 aggregate principal amount of its 8.625% senior subordinated unsecured notes due 2018 (the “ Original Notes”). The Company’s obligations under the Original Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior subordinated unsecured basis, by each of the Subsidiaries (as defined below) listed on the signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Original Notes and the Guarantees are referred to herein as the “Securities.” The respective principal amounts of the Original Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Original Notes are to be issue
Inverness Medical Innovations, Inc. $100,000,000 7.875% Senior Notes due 2016 PURCHASE AGREEMENTPurchase Agreement • September 28th, 2009 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
Introductory. Inverness Medical Innovations, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers named in Schedule A (the “Initial Purchasers”) $100,000,000 aggregate principal amount of its 7.875% senior unsecured notes due 2016 (the “Original Notes”). The Company’s obligations under the Original Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior unsecured basis, by each of the Subsidiaries (as defined below) listed on the signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Original Notes and the Guarantees are referred to herein as the “Securities.” The respective principal amounts of the Original Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Original Notes are to be issued under an indenture dated as of August 11, 2009
